Trikafta and Me

Cystic Fibrosis, a genetic condition that damages the lungs and digestive system, affects about 70,000 people worldwide. There is no known cure but transformative drugs are helping to improve quality of life. One of these is Trikafta.

Tune in to hear nursing student, Annaka Haynes, who shares her journey from being diagnosed at 6-weeks old to her life today, and her ambitions for the future.

Trikafta, developed by Vertex Pharmaceuticals, was first approved by the FDA on October 21, 2019. This treatment is a triple combination regimen for Cystic Fibrosis patients starting at ages 2 years and older who have at least one F508del mutation in the Cystic Fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.